PMID- 17215857
OWN - NLM
STAT- MEDLINE
DCOM- 20070413
LR  - 20151119
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 21
IP  - 3
DP  - 2007 Mar
TI  - Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and 
      advanced myelodysplastic syndrome: association with clinical behavior and outcome 
      of induction therapy.
PG  - 480-8
AB  - beta-2 Microglobulin (beta2M), a subunit of human leukocyte antigen-class I 
      (HLA-I), is well established as a marker of prognosis in various solid tumors and 
      hematologic malignancies. The prognostic role of intact free-circulating HLA-I 
      (sHLA-I) is less well understood. We compared the clinical relevance of plasma 
      levels of sHLA-I and beta2M in patients with acute myeloid leukemia (AML; n=209) 
      or advanced myelodysplastic syndrome (MDS; n=98). sHLA-1 and beta2M levels were 
      significantly higher in AML and MDS patients than in control subjects, but did 
      not differ significantly between the two disease groups. In AML patients, 
      multivariate analysis showed both sHLA-1 and beta2-M to be highly predictive of 
      complete remission (CR), survival and duration of complete response (CRD). In 
      MDS, the predictive value of the two markers differed substantially from one 
      another: beta2M was associated with survival, CR and CRD, whereas sHLA-I was not. 
      These findings not only establish the role of sHLA-I as a tumor marker in AML but 
      also support that MDS is clinically and biologically distinct from AML. sHLA-I 
      has been reported to be an immunomodulator inhibiting the cytotoxic effects of 
      T-lymphocytes, which may offset its predictive value for disease aggressiveness 
      in patients with MDS.
FAU - Albitar, M
AU  - Albitar M
AD  - Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan 
      Capistrano, CA 92690, USA. maher.x.albitar@questdiagnostics.com
FAU - Johnson, M
AU  - Johnson M
FAU - Do, K A
AU  - Do KA
FAU - Day, A
AU  - Day A
FAU - Jilani, I
AU  - Jilani I
FAU - Pierce, S
AU  - Pierce S
FAU - Estey, E
AU  - Estey E
FAU - Kantarjian, H
AU  - Kantarjian H
FAU - Keating, M
AU  - Keating M
FAU - Verstovsek, S
AU  - Verstovsek S
FAU - O'brien, S
AU  - O'brien S
FAU - Giles, F J
AU  - Giles FJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20070111
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (beta 2-Microglobulin)
RN  - 04079A1RDZ (Cytarabine)
RN  - 7M7YKX2N15 (Topotecan)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*blood
MH  - Cytarabine/administration & dosage
MH  - Disease Progression
MH  - Female
MH  - HLA Antigens/*blood
MH  - Humans
MH  - Idarubicin/administration & dosage
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid/*blood/drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*blood/drug therapy/mortality
MH  - Neoplasm Proteins/*blood
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - Remission Induction
MH  - Solubility
MH  - Topotecan/administration & dosage
MH  - Treatment Outcome
MH  - Vidarabine/administration & dosage/analogs & derivatives
MH  - beta 2-Microglobulin/*blood
EDAT- 2007/01/12 09:00
MHDA- 2007/04/17 09:00
CRDT- 2007/01/12 09:00
PHST- 2007/01/12 09:00 [pubmed]
PHST- 2007/04/17 09:00 [medline]
PHST- 2007/01/12 09:00 [entrez]
AID - 2404506 [pii]
AID - 10.1038/sj.leu.2404506 [doi]
PST - ppublish
SO  - Leukemia. 2007 Mar;21(3):480-8. doi: 10.1038/sj.leu.2404506. Epub 2007 Jan 11.